MARKET INTELLIGENCE REPORT
Ashley Chacko
Senior Vice President, Market Intelligence and Strategic Planning at Healthcare Outcomes Performance Company (HOPCo)
Modern Healthcare 2/6/2025
·???????? A 10% tariff on goods from China and proposed 25% tariffs on goods from Mexico and Canada, is jolting a healthcare industry that relies heavily on imported medical devices and supplies.
·???????? The American Hospital Association requested an exemption from the tariffs?for medical devices and pharmaceuticals made in the three countries.
?
U.S. Food & Drug Administration 1/30/2025
·???????? The U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults.
·???????? Journavx is the first drug to be approved in this new class of pain management medicines.
?
Modern Healthcare 2/4/2025
·???????? There may be a new president in the White House and a new majority on Capitol Hill, but major healthcare provider trade groups remain mainly focused on perennial issues as they seek to influence policymaking in 2025.
·???????? Medicare reimbursements, Medicaid funding, health insurance prior authorization requirements and workforce issues top the policy agendas for organizations representing hospitals, physicians and long-term care providers.
?
Beckers 1/24/2025
·???????? An increasing number of health systems are bringing pharmacy benefit manager services in house, a trend driven by a goal to reduce prescription drug costs, improve transparency and have more control over patient care.?
·???????? As PBM services have traditionally been dominated by large companies such as CVS Caremark, Express Scripts and OptumRx, health systems are starting to create alternatives.